Dystrophic Epidermolysis Bullosa (DEB) is an ultra rare genetic disease with no currently approved treatments. In this Access90, Precision’s Will Derrickson discusses the unique market access considerations for Krystal Biotech’s anticipated launch of B-VEC, a non-invasive treatment for DEB and the first ever topical gene therapy.

Watch the video HERE!